68Ga-PSMA-11

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

4mo

TLXPhase 3$2.6B

68Ga-PSMA-11 Phase 3 Results Expected

68Ga-PSMA-11• Biochemical Recurrence of Malignant Neoplasm of Prostate204

Jun 15Estimated

00%

Competitive Landscape

0 competitors in Biochemical Recurrence of Malignant Neoplasm of Prostate

Drug Information

Target Indication

Biochemical Recurrence of Malignant Neoplasm of Prostate

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

TLX

Telix Pharmaceuticals Ltd

Related Pipeline

Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Clear Cell Renal Cell Carcinoma

Metastatic Castration-resistant Prostate Cancer

Prostate Cancer